Navigation Links
New strategy in tumor treatment
Date:7/20/2009

A new strategy proposed by researchers at Dartmouth Medical School and Amtek, Hanover, NH may treat tumors that do not respond to conventional treatment. The study, which was published on May 29th in the open access, peer reviewed journal PLoS ONE, uses a combination of two agents to selectively kill tumors while protecting healthy cells.

In previous studies, researchers discovered that a specific enzyme known as methylthioadenosine phosphorylase (MTAP) is missing in 35 to 70 percent of lung, pancreatic and biliary tract cancer, melanoma, glioblastoma, osteosarcoma, soft-tissue sarcoma, mesothelioma, and T-cell acute lymphoblastic leukemia. Although information on the incidence of MTAP-deficiency in breast cancer is still limited, researchers believe it is probably significant.1 Since the discovery of MTAP-negative tumors, there have been several proposals, over the years, to take advantage of the frequent absence of MTAP in so many lethal cancers. None of these proposals, however, has led to successful clinical use.

Dr. Martin Lubin, Professor of Microbiology, Emeritus, and co-author Adam Lubin of Amtek have offered a new approach. They say, "Our strategy consists of two agents. One drug is given that is toxic both to cancer cells and to normal host tissues. A second, but non-toxic, drug is also given, which protects normal tissues from the toxic action of the first agent. This two-drug combination therapy kills tumor cells while normal tissues are well protected." They go on to state, "Among the drugs used to kill the tumor cells, two -- thioguanine and fluorouracil (or its prodrug Xeloda) - are already in clinical use. In general, the dose of these drugs is limited by toxic side effects. However, with our strategy, greatly increased doses might be used and tumors not susceptible to low doses could be attacked successfully at higher doses, without harm to host tissues."

To assess the selective killing of tumor cells when they were present in excess of normal cells, the researchers designed co-culture experiments in vitro and animal studies are now in progress.

"We hope that successful animal studies will lead to clinical application as soon as possible," Dr. Lubin said.


'/>"/>

Contact: Jen Laloup
jlaloup@plos.org
415-624-1220
Public Library of Science
Source:Eurekalert

Related medicine news :

1. AWT Management Announce Aggressive Growth and Acquisition Strategy
2. Coalition America Announces Addition of Mollie Gordon Brown as Chief Strategy Officer
3. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
4. More Than 100 Organizations Call for a National AIDS Strategy to End the Epidemic in the United States
5. Penn Veterinary Medicine report new strategy to create genetically modified animals
6. Novel strategy under study for aggressive leukemia
7. AIDS Action Council Commends Senator Edwards for Endorsing a National HIV/AIDS Strategy
8. Blue Shield of California Names Vincent Coppola Vice President of Strategy and Business Development
9. Scientific Publications Strategy & Delivery Shifts from Marketing to Medical
10. Cheryl Fossum Graham Joins Knopp Neurosciences as Head of Regulatory and Development Strategy
11. Computerized training of working memory is a promising therapeutic strategy in ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2017)... ... May 28, 2017 , ... ... is proud to announce that Jorge Fernandez-Silva, M.D., has joined its new Melbourne ... a specialty that concentrates on minimally invasive techniques to treat and manage many ...
(Date:5/27/2017)... ... May 26, 2017 , ... A May 8 article on CBCNews ... or respiratory issues that are not responsive to antibiotics nevertheless obtain prescriptions for them. ... largely responsible for the problem both in Canada and the United States. Dr. Michael ...
(Date:5/27/2017)... , ... May 27, 2017 , ... From May 21-23, ... Oticon. The three-day event was held at the Marriott Syracuse Downtown Hotel in Syracuse, ... hearing brand and network of independent hearing healthcare providers to help them stay ahead ...
(Date:5/26/2017)... ... 26, 2017 , ... The American Parkinson Disease Association’s ... grant submissions all vying for nearly $1,000,000 in funding that will be awarded ... American Parkinson Disease Association (APDA) is focused on advancing scientific research that will ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Amir Qureshi, ... System, a powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita SCS System ... “We are pleased to be the first in Arkansas to introduce the most powerful ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... WASHINGTON , May 9, 2017  Demonstrating ... the board of directors for the Pharmaceutical Research ... criteria for membership. Biopharmaceutical companies will now have ... in order to be eligible to join PhRMA. ... criteria, the board is sending a clear message ...
(Date:5/8/2017)... May 8, 2017 MACRA replaces the ... fee for service reimbursement. Black Book Research crowdsource-surveyed 8,845 ... 1.       The Market for MIPS Compliance Technology is ... physician practices with 3 or more clinicians seek to ... Q4. "Given the magnitude of the changes, the hunt ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke ... one of the most important methods to prevent a ... the Centers for Disease Control and Prevention, undetected and ... 1 Omron, the global leader in personal heart ... the elimination of heart attack and stroke and is ...
Breaking Medicine Technology: